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ATP is an important mediator of urgency in women with detrusor overactivity (DO). In order to understand how different degrees
of bladder stretch elicited ATP release in DO patients compared with controls, sequential aliquots were collected during cystometry
and ATP release was measured at each degree of bladder filling, in female patients with DO and controls. In both DO and control
groups, ATP releasewas induced during bladder filling, suggesting that stretch stimulated furtherATP release.However, the luminal
ATP concentrations were already high at early filling stage (200mL), which was even greater than those at the later filling stages
(400mL andmaximum cystometric capacity, MCC), indicating that a substantial ATP release has been induced during early filling
(200mL) in bothDOand controls. InDO,ATP release at 200mLwas significantly higher in thosewith lowfirst desire to void (FDV)
(≤200mL) than in those with higher FDV (>200mL); this may suggest that ATP release at early stretch may play an important role
in urgency (early sensation) in DO. ATP concentrations remained unchanged after voiding, suggesting that voiding did not further
induce ATP release into intraluminal fluid.
1. Introduction
The urothelium, which was once regarded as an inert, pro-
tective barrier, plays a key role in bladder sensory and motor
functions [1]. The hypothesis that the purine nucleotide ATP
is a neurotransmitter responsible for nonadrenergic, noncho-
linergic neurotransmission was proposed in 1972 and termed
purinergic signalling [2]. More recently, both animal and
human studies show that nonneuronal ATP is released
from the bladder urothelium in response to stretch [3–6].
Besides urothelial cells, cultured pig myofibroblasts were also
reported to release ATP in response to stretch [3]. In rat
bladder, intravesical application of ATP has been shown to
induce detrusor overactivity [7].
Urothelial derived mediators, such as acetylcholine and
ATP, signal the sensation of bladder fullness to the central
nervous system, thus triggering the micturition reflex [8].
Such mediators act upon specific receptors such as P2X
receptors located on suburothelial afferent nerves [9], with
possible involvement of myofibroblasts [10]. In addition to
stretch, ATP is also released from animal bladder urothelial
cells and tissue strips in response to capsaicin and acid [3, 5].
In human subjects, OAB was shown to be associated with
increased ATP release [11, 12].
Previous studies have explored the hypothesis that ATP in
bladder luminal fluid could be a marker for the sensation of
“urgency” as experienced by patients with overactive bladder
symptoms [13, 14]. An inverse correlation between the intrav-
esical concentration of ATP and bladder volume at FDV has
previously been reported in two groups: patients with uro-
dynamically proven DO [13] and patients with clinical OAB
and low FDV [14]. However, the mechanism responsible for
this was not elucidated.
Stretch is considered to be a major stimulus for ATP
release in the bladder and it was hypothesized therefore that
more ATP should be released as the bladder fills, with the
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highest ATP levels occurring at the end of the filling stage
in accordance with murine studies which showed increased
ATP release with increased intravesical pressure [15]. How-
ever, to our knowledge there are no reports indicating exactly
when ATP is released during human bladder filling or how
ATP release is influenced by the degree of bladder stretch.
Therefore, we performed cystometry in women, collecting
consecutive samples of bladder fluid at 200mL and 400mL
and MCC for sequential ATP measurement. We recruited
control patients and those with DO in order to characterise
and compare the pattern of sequential ATP release in these
two groups.
2. Materials and Methods
2.1. Cystometry. Each female patient was catheterised to
empty the bladder completely for routine clinical cystometry
[16], with the exception that dual lumen catheters were em-
ployed. A CSU was sent for culture and patients with proven
bacterial cystitis (“UTI” 108 cfu/L with pyuria >10/HPF) were
excluded from subsequent analysis. Female patients gave
informed consent in accordance with approval from the
South Eastern Sydney human research ethics committee
(SESIAHS HREC 06/11).
Saline at room temperature (approximately 25∘C) was
infused into the bladder at a filling rate of 75mL/min
(medium-fill) [16] as described previously [13]. As per rou-
tine, volumes were noted when the patient felt FDV and
reachedmaximum cystometric capacity (MCC), (the volume
at which the patient feels she can no longer delay micturition
[16]), when filling was stopped. Tap water stimuli and erect
provocation were routinely performed. At the end of cys-
tometry, the patient voided the filling solution into a clean
uroflow chamber, in private. The presence of any detrusor
contractions during filling, or provocation such as the sound
of running tapwater or changing supine to erect position, was
noted.
Patients were characterised as (a) idiopathic DO, with
involuntary detrusor contractions during the filling phase
which may be spontaneous or provoked, or (b) control, that
is, pure urodynamic stress incontinence, involuntary leakage
of urine during increased abdominal pressure in the absence
of detrusor contractions, and no symptoms of urgency.
Patients with the following were excluded: (a) bladder pain
syndrome (FDV < 200mL with bladder pain, and MCC <
400mL), (b) voiding dysfunction (detrusor pressure (Pdet)
at maximal flow greater than 60 cm H
2
O), (c) incomplete
voiding (postvoid residual volume > 100mL), or (d) evidence
of spinal cord or central neurological disease.
2.2. Sampling and ATP Measurements. When the filling vol-
ume reached 200mL, 400mL, and MCC, the infusion was
paused for sample collection. These volumes were chosen as
fixed values that approximate the commonly observed filling
volumes for first desire to void and maximal capacity in
patients with DO (see discussion). At each volume, the first
10mL in the collecting catheter (“deadspace”) was aspirated
and discarded; then, a further 5mL of intravesical filling fluid
was collected. After voiding, fluid from the uroflow chamber
was collected (known as “voided volume,” VV). Each woman
thus yielded four samples for ATP assay. Immediately after
collection, samples were transported on ice from the clinic to
the laboratory in the adjacent building and then ATP assayed
immediately.
ATP concentration (in nM) was measured in duplicate
per sample, using a GloMax 20/20 luminometer and a biolu-
minescence assay (Sigma). A standard curve was constructed
using freshly made standards (10−5 to 10−10M and blank)
from frozen concentrated ATP stock. The total amount of
ATP (in nmoles) contained in each sample was then cal-
culated by multiplying the filling volume (200mL, 400mL,
MCC, or VV) by its corresponding ATP concentration.
2.3. Statistical Analysis. ATP data were not normally dis-
tributed (𝑃 < 0.05, D’Agostino & Pearson omnibus normality
test) andwere expressed asmedian (interquartile range, IQR).
Nonparametric statistical analyses were performed using
GraphPad Prism 6.0 software (SanDiego, USA). Comparison
of ATP levels in the different samples was performed by
Friedman ANOVA with Dunn’s multiple comparisons test
(Figures 1 and 4) or using a Mann-Whitney test when two
unmatched groups were compared (Figure 2) or a Wilcoxon
test when matched groups were compared (Figure 3). Meth-
ods, definitions, and units conform to the standards rec-
ommended by the International Continence Society except
where specifically noted.
3. Results and Discussions
3.1. Stretching Is a Stimulate to Induce Further ATP Release
in Both DO and Controls. Although ATP release is induced
by urothelial stretch during bladder filling, it is unclear
whether stretch-induced ATP is involved in triggering blad-
der contraction, either at physiological maturation or during
pathological conditions such as DO, and the pattern of ATP
release in human bladder and its association with bladder
sensation have not been clearly understood. Traditional ani-
mal models cannot provide this information, because of the
small bladder volume in rats and mice and the inability to
assess the sensations of bladder filling in the rodent. Results
from in vitro laboratory studies reporting ATP release from
human bladder urothelium/lamina propria strips have shown
a very marked increase in stretch-induced ATP release in
DO, compared with control [12]. Using urodynamic fluid to
investigate ATP release has become a valuable tool to answer
these questions under true physiological condition relevant
to patients.
To investigate how bladder stretch could induce ATP
release, we also chose to collect samples at volumes of 200mL,
which approximates the FDV in most patients (median FDV
in DO 167mL and control 200mL, Table 1), and a filling
volume of 400mL, which is close to the MCC (median MCC
430mL) in most DO patients, in addition to sampling at
MCC and in voided fluid. We compared ATP release in these
consecutive intraluminal fluid samples from each patient.
These intraluminal fluid samples have been generated during
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Figure 1: Comparison of total ATP (nmoles) in bladder fluid collected at volumes of 200mL and 400mL and at MCC, in control (𝑛 = 18)
(a) and DO (𝑛 = 27) (b). ATP content significantly increased between filling volumes of 200mL and 400mL and between 200mL andMCC.
Data were analyzed by the Friedman test followed by Dunn’s multiple comparison test. (∗∗ = 𝑃 < 0.01; ∗∗∗ = 𝑃 < 0.001).
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Figure 2: Comparison of ATP concentrations in bladder fluid collected at volumes of 200mL and 400mL and at MCC for control (𝑛 = 18)
(a) and DO (𝑛 = 27) (b) patients. In this and subsequent figures, data points are from individual patients, showing median and interquartile
range. Data were analyzed by the Friedman test followed by Dunn’s multiple comparison test.
Table 1: Patient urodynamic characteristics.
Control (median (IQR)) DO (median (IQR))
𝑛 18 27
Age (years) 60.5 (47–70) 59 (54–66)
FDV (mL) 200 (170–265) 167 (100–277)
MCC (mL) 492 (450–500) 430 (400–500)
∗Max Pdet during filling (cmH2O) 6.5 (5–9.25) 33 (17–46)
Detrusor contractions during cystometry 0 27
VV (mL) 485 (415–532.5) 417 (380–500)
∗Maximal detrusor pressure during filling or provocation.
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Figure 3: Comparison of ATP release at a bladder volume of 200mL. For control (a) and DO patients (b), the data have been divided into
two groups of low (≤200mL) and higher FDV (>200mL).The two control groups of low (𝑛 = 9) and high (𝑛 = 9) FDV showed no significant
difference (𝑃 = 0.33), whereas there was a significantly higher concentration of ATP in the DO group with low FDV (𝑛 = 17), compared to
the DO group with higher FDV (𝑛 = 10) (𝑃 = 0.01, Mann-Whitney test).
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Figure 4: Comparison of ATP concentration before and after voiding in (a) control (𝑛 = 18) and (b) DO patients (𝑛 = 27). For control
patients, there was no difference in ATP concentration of urodynamic fluid before MCC or after voiding (VV). For DO patients, there was a
significant decrease in ATP concentration in VV compared with MCC (𝑃 = 0.01, Wilcoxon test).
routine urodynamic testing under standard clinical condi-
tions which occurs at a supraphysiological filling rate (75mL/
min) [16].
Cystometry with measurement of ATP at the four filling
volumes was performed on 53 women (age 28–87 yrs). Eight
subjects with UTI on the test day and 2 subjects with voiding
dysfunction were excluded, yielding 27 patients with DO and
18 control patients (Table 1).
The total amount of ATP (in nmoles) at each bladder
volumewas examined. For both control (Figure 1(a)) andDO
(Figure 1(b)), there was a significant increase in the total
amount of ATP, in nmoles, between 200mL and 400mL, as
well as between 200mL andMCC; the total amount of ATP in
the intraluminal fluid (in nmoles) was the lowest at the lowest
bladder filling volume (total ATP median values (in nmoles)
at 200mL, 400mL, andMCC are 8.8, 13.1, and 14, for DO, and
8.9, 18.1, and 20.2, for controls). Note that ATP was released
continuously throughout the urodynamic test in both DO
and control and that the total ATP content in the intraluminal
fluid increased during filling, that is, from 200mL to 400mL,
which agreed with the initial hypothesis that ATP release was
induced by bladder stretch in both DO and controls.
We have also compared the difference in ATP release
between DO and control groups at each filling/sampling
point, but we did not see any significant difference between
the two groups. One of the reasons for this could be the
variations in ATP release in individuals, which made it too
hard to see the difference between two groups. This is not
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a surprise as therewas no significant difference inATP release
between DO and control patients with a much larger sample
size in a previous study [13].
3.2. Substantial ATP Released at the Early Bladder Filling
Stage. We also compared the ATP concentrations according
to the filling volumes and determined that in both control
(Figure 2(a)) and DO (Figure 2(b)) patients, there was a sig-
nificant difference in ATP concentration at the three different
bladder volumes (Friedman test). Overall, in both control and
DO patients the ATP concentration was higher at the early
filling stage (200mL, median ATP 44.5 nM control; 43.8 nM
DO) compared with later stages (MCC, median ATP 40.2
control; 31.3.7 nM DO).
This is a surprising and important finding. This indicates
that there was substantial ATP release at early filling volumes
in both DO and controls, and early ATP release may play an
important role in bladder function and dysfunction, that is,
early sensation or urgency for DO.
3.3. Early ATP Concentration Is Related to the First Desire Vol-
ume (FDV) in DO Patients. In the DO patients, the median
FDV was 167mL, with values ranging between 85 and
400mL. In order to investigate whether FDV was associated
withATP release, patientswere divided into two groups based
on low FDV (≤200mL) and higher FDV (>200mL). In con-
trol patients, no difference in ATP concentration in intraves-
ical fluid at 200mL was seen between the two groups (FDV
less than 200mL (ATP median = 40.2 nM) and FDV more
than 200mL (ATP median = 76.5 nM)) (Figure 3(a)). How-
ever, in DO patients, the concentration of ATP in intravesical
fluid at 200mLwas significantly higher in patientswithFDV≤
200mL than those with FDV > 200mL (Figure 3(b)). The
same analysis was applied to the data sets from the 400mL,
MCC, and VV samples, but no association was shown be-
tween FDV and ATP release at these volumes (data not
shown).
The fact that DO patients with a lower FDV (≤200mL)
had higher ATP concentrations (ATP median 62.7 nM) at
an earlier bladder volume, compared with DO patients who
had a higher FDV (>200mL) (ATPmedian 16.1 nM), suggests
that the early ATP release may play an important role in
DO patients, which may cause urgency. The previous clinical
studies have also found that ATP in voided urodynamic fluid
was inversely correlated with the FDV in DO [13] and OAB
[14] patients, but not controls.This current study supports the
supposition that it is the early ATP release which is important
to the sensation of urgency in DO patients.
Although ATP can be degraded by membrane-bound
ectoATPases, studies have shown that there is little ectoAT-
Pase activity associated with the apical surface of the urothe-
lium [17]; thus the intravesical ATPmeasured may reflect the
ATP released from the urothelial cells. Moreover, the source
of the ATP is assumed to be from the urothelial cells, but this
was not able to be determined from our in vivo study. The
ATP in bladder intraluminal fluid might be released directly
from urothelial cells into the lumen and/or could diffuse
into the lumen from various sources within the bladder
wall, such as from the suburothelial myofibroblasts. Diffusion
into the lumen from suburothelial cells would be limited by
the intact bladder urothelium and also by the ectoATPase
activity associatedwith intermediate and basal urothelial cells
and also with the lamina propria [17]. However, a reduced
ectoATPase activity in laboratory samples of OAB has been
reported [18]; thus, more ATP may diffuse into deep sites of
bladder wall, enhancing stretch-induced signalling pathways
inducing urgency or involuntary contractions.These findings
may explainwhy the earlyATP release plays an important role
in early sensation (urgency) in DO but not in controls.
3.4. Voiding Did Not Further Induce ATP Release. Previous
studies have reported that ATP plays a role in the bladder
as a purinergic neurotransmitter in functional motor [6] as
well as sensory bladder disorders [12]. Thus ATP might also
appear in the bladder as a result of parasympathetic nerve
stimulation to the detrusor during voiding [19].
In order to investigate whether a micturition contraction
might increase ATP release in the bladder, we compared the
ATP concentration before voiding (MCC) and after voiding
(VV). The results showed no significant difference in ATP
concentration between MCC (ATP median = 40.2 nM) and
voided volumes (ATP median = 36.8 nM) in control patients
(Figure 4(a)); that is, ATP content remained unchanged
after voiding. In DO patients (Figure 4(b)), there was no
evidence of any increase in ATP release and in fact the ATP
concentration was slightly lower in voided fluid (VV) (ATP
median= 28.4 nM) than in bladder intraluminal fluid atMCC
(ATP median = 31.3 nM) (𝑃 = 0.01, Wilcoxon test). This
suggests that the voiding contraction does not contribute
further to intravesical ATP release in bladder lumen.
This is not surprising as ATP released frommotor nerves
will be deep in the detrusormuscle layer and unlikely to reach
the bladder lumen due to abundant ecto-ATPase in lamina
propria and smooth muscle [17]. Instead of increased ATP
after voiding, we have noticed a decreased intravesical ATP
after voiding in DO patients in our study. It is possible
that, during micturition, the intravesical ATP is exposed to
ectoATPase located on exfoliated urothelial cells [20] and,
therefore, ATP may undergo enhanced degradation during
or after voiding.
4. Conclusions
For the first time ATP release during bladder filling has been
investigated in sequential intraluminal fluid samples in fe-
male patients with or without DO.This study has shown that
total amount of ATP in intraluminal fluid (in nmoles) contin-
ued to increase from lower bladder volume (200mL) to high-
er bladder volume (400mL and MCC) in both DO and con-
trols.The study demonstrates that stretch (bladder filling) can
induce further ATP release in human bladder. Interestingly,
we have noticed that there was a substantial ATP release in
intraluminal fluid in the early filling stage, that is, bladder fill-
ing volume of 200mL.The results also show that ATP release
at 200mLfilling volume is related to FDVonly inDOpatients
but this relationship was not observed in the control group.
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These data indicate that ATP release at early bladder filling
may play an important role in increased bladder sensations,
for example, urgency, in DO patients.
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